CART-38 / University of Pennsylvania - LARVOL DELTA

CART-38 in Adult AML and MM Patients (clinicaltrials.gov) - P1 | N=11 | Terminated | Sponsor: University of Pennsylvania | N=36 ➔ 11 | Trial completion date: May 2041 ➔ Feb 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: May 2041 ➔ Feb 2025; Administrative decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CD34 • CD38

CART-38 in Adult AML and MM Patients (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CD34 • CD38

CART-38 in Adult AML and MM Patients (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: University of Pennsylvania | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CD34 • CD38

CD38 as a pan-hematologic target for chimeric antigen receptor T cells. (PubMed, Blood Adv) - "In a xenograft model of normal human hematopoiesis, CART-38 resulted in the expected reduction of hematopoietic progenitors, which warrants caution and careful monitoring of this potential toxicity when translating this new immunotherapy into the clinic. Deploying CART-38 against multiple CD38-expressing malignancies is significant, as it expands the potential for this novel therapy to impact diverse patient populations."

CAR T-Cell Therapy • IO biomarker • Journal • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • CD38

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway (ASH 2022) - P2 | "Previous work has shown the CD38 targeting monoclonal antibody Daratumumab (Dara) is efficacious in patient derived xenograft (PDX) models of T-ALL in NSG mice (PMID: 29305553) and is currently being investigated in clinical trials in pediatric T-ALL (NCT03384654). Using metabolic profiling we identify novel changes in the polyamine synthesis pathway in CD38KO cell lines and in blasts treated with Dara and CART38. Blockade of the polyamine synthesis pathway with DFMO potentiates the action of dara in a PDX model of pediatric T-ALL. Ongoing studies are combining DFMO with CART38 in PDX."

IO biomarker • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia

CART-38 in Adult AML and MM Patients (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: University of Pennsylvania | Trial completion date: Sep 2040 ➔ May 2041 | Initiation date: Sep 2022 ➔ May 2023 | Trial primary completion date: Sep 2040 ➔ May 2041

Trial completion date • Trial initiation date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CD34 • CD38

CART-38 in Adult AML and MM Patients (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: University of Pennsylvania

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CD34 • CD38